Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$98.46 USD

98.46
1,399,883

-0.62 (-0.63%)

Updated May 20, 2024 04:00 PM ET

After-Market: $98.46 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 249)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).

Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPME

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

by Zacks Equity Research

Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

by Zacks Equity Research

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Maharathi Basu headshot

5 Broker-Loved Stocks That Hold Promise Despite Volatility

by Maharathi Basu

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

by Zacks Equity Research

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Zacks.com featured highlights include NetApp, Installed Building Products, Ralph Lauren, Applied Materials and Cardinal Health

by Zacks Equity Research

NetApp, Installed Building Products, Ralph Lauren, Applied Materials and Cardinal Health are part of the Zacks Screen of the Week article.

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

by Zacks Equity Research

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption

by Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva's strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite

by Zacks Equity Research

GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access

by Zacks Equity Research

With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

by Zacks Equity Research

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Sweta Killa headshot

5 Solid Dividend Growth Stocks to Buy

by Sweta Killa

NetApp (NTAP), Installed Building (IBP), Ralph Lauren (RL), Applied Materials (AMAT), and Cardinal Health (CAH) could outperform the market this year.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.

Here's Why Cardinal Health (CAH) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

by Zacks Equity Research

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.